253 related articles for article (PubMed ID: 2680986)
21. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
Devi SJ; Schneerson R; Egan W; Ulrich TJ; Bryla D; Robbins JB; Bennett JE
Infect Immun; 1991 Oct; 59(10):3700-7. PubMed ID: 1716613
[TBL] [Abstract][Full Text] [Related]
22. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
Zhang H; Zhong Z; Pirofski LA
Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
[TBL] [Abstract][Full Text] [Related]
23. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.
Probert M; Zhou X; Goodall M; Johnston SA; Bielska E; Ballou ER; May RC
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549
[TBL] [Abstract][Full Text] [Related]
24. Finite-element model of interaction between fungal polysaccharide and monoclonal antibody in the capsule of Cryptococcus neoformans.
Rakesh V; Schweitzer AD; Zaragoza O; Bryan R; Wong K; Datta A; Casadevall A; Dadachova E
J Phys Chem B; 2008 Jul; 112(29):8514-22. PubMed ID: 18588334
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.
Oscarson S; Alpe M; Svahnberg P; Nakouzi A; Casadevall A
Vaccine; 2005 Jun; 23(30):3961-72. PubMed ID: 15917118
[TBL] [Abstract][Full Text] [Related]
26. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
[TBL] [Abstract][Full Text] [Related]
27. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.
Deshaw M; Pirofski LA
Clin Exp Immunol; 1995 Mar; 99(3):425-32. PubMed ID: 7882565
[TBL] [Abstract][Full Text] [Related]
28. Capsular polysaccharides of Cryptococcus neoformans.
Bhattacharjee AK; Bennett JE; Glaudemans CP
Rev Infect Dis; 1984; 6(5):619-24. PubMed ID: 6209768
[TBL] [Abstract][Full Text] [Related]
29. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
Nussbaum G; Anandasabapathy S; Mukherjee J; Fan M; Casadevall A; Scharff MD
Infect Immun; 1999 Sep; 67(9):4469-76. PubMed ID: 10456888
[TBL] [Abstract][Full Text] [Related]
30. Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.
Gates-Hollingsworth MA; Kozel TR
Mol Microbiol; 2009 Oct; 74(1):126-138. PubMed ID: 19758241
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
Cleare W; Cherniak R; Casadevall A
Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
[TBL] [Abstract][Full Text] [Related]
32. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
33. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.
Kozel TR; Levitz SM; Dromer F; Gates MA; Thorkildson P; Janbon G
Infect Immun; 2003 May; 71(5):2868-75. PubMed ID: 12704160
[TBL] [Abstract][Full Text] [Related]
34. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.
Nakouzi A; Valadon P; Nosanchuk J; Green N; Casadevall A
Infect Immun; 2001 May; 69(5):3398-409. PubMed ID: 11292763
[TBL] [Abstract][Full Text] [Related]
35. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.
Nakouzi A; Zhang T; Oscarson S; Casadevall A
Vaccine; 2009 Jun; 27(27):3513-8. PubMed ID: 19464529
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
Mukherjee S; Lee S; Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1994 Mar; 62(3):1079-88. PubMed ID: 8112842
[TBL] [Abstract][Full Text] [Related]
37. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.
Cherniak R; Morris LC; Belay T; Spitzer ED; Casadevall A
Infect Immun; 1995 May; 63(5):1899-905. PubMed ID: 7729900
[TBL] [Abstract][Full Text] [Related]
38. Protein-polysaccharide interactions. A monoclonal antibody specific for the capsular polysaccharide of Cryptococcus neoformans.
Otteson EW; Welch WH; Kozel TR
J Biol Chem; 1994 Jan; 269(3):1858-64. PubMed ID: 8294434
[TBL] [Abstract][Full Text] [Related]
39. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans.
Feldmesser M; Kress Y; Casadevall A
J Infect Dis; 1998 Jun; 177(6):1639-46. PubMed ID: 9607844
[TBL] [Abstract][Full Text] [Related]
40. [Recognition of intact cells from Cryptococcus neoformans by the anti-glucuronoxylomannan 4B3 monoclonal antibody].
Gato Armas R; Martínez Machín G; Rodríguez Sánchez H; Otero González A; Sarracent Pérez J; Illnait Zaragozi MT
Rev Cubana Med Trop; 2006; 58(2):159-61. PubMed ID: 23427436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
